News | November 02, 2023
Zydus acquires UK based LiqMeds Group
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Subscribe To Our Newsletter & Stay Updated
